These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36652936)

  • 1. In Chronic Spontaneous Urticaria, Complete Response to Antihistamine Treatment Is Linked to Low Disease Activity.
    Türk M; Ertaş R; Şahiner ÜM; Kolkhir P; Şekerel BE; Soyer Ö; Avcı A; Atasoy M; Özyurt K; Türk Y; Zeydan E; Maurer M
    Int Arch Allergy Immunol; 2023; 184(5):421-432. PubMed ID: 36652936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 3. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria.
    Ayse Ornek S; Orcen C; Church MK; Kocaturk E
    Int Immunopharmacol; 2022 Nov; 112():109198. PubMed ID: 36115277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated With Refractoriness to an Up to Fourfold Dosage of Antihistamines in Isolated Chronic Spontaneous Urticaria.
    Wongjirattikarn R; Chaowattanapanit S; Foocharoen C; Sawanyawisuth K; Choonhakarn C; Julanon N; Utchariyaprasit E
    J Cutan Med Surg; 2022; 26(6):593-599. PubMed ID: 36172833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
    J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
    Abe N; Bohgaki M; Kasahara H
    Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don't Know.
    Terhorst-Molawi D; Fox L; Siebenhaar F; Metz M; Maurer M
    Am J Clin Dermatol; 2023 May; 24(3):397-404. PubMed ID: 36810982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Melé-Ninot G; Serra-Baldrich E; Spertino J; Guilarte M; Ribó González P; Lleonart-Bellfill R; Figueras-Nart I; Bonfill-Ortí M; Depreux N; Sala-Cunill A; Bielsa-Marsol I; Baliu-Piqué C; Sanmartín-Novell V; Garcia-Navarro X; Expósito-Serrano V; Garnica-Velandia D; Diaz-Sarrió MC; Gómez-Armayones S; Gich Saladich I; Giménez-Arnau A
    Eur J Dermatol; 2022 Sep; 32(5):629-631. PubMed ID: 36468733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
    Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
    JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotic as an adjuvant therapy in chronic urticaria: a blinded randomized controlled clinical trial.
    Atefi N; Fallahpour M; Sharifi S; Ghassemi M; Roohaninasab M; Goodarzi A
    Eur Ann Allergy Clin Immunol; 2022 May; 54(3):123-130. PubMed ID: 33939347
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors of uncontrolled symptoms using the standard dose of second-generation H1 -antihistamines in chronic spontaneous urticaria children.
    Koosakulchai V; Yuenyongviwat A; Sangsupawanich P
    Asian Pac J Allergy Immunol; 2022 Jun; 40(2):121-125. PubMed ID: 32061244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
    Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.
    Özçeker D; Can PK; Terzi Ö; Ornek SA; Değirmentepe EN; Kızıltac K; Sarac E; Kocatürk E
    Pediatr Allergy Immunol; 2023 Feb; 34(2):e13925. PubMed ID: 36825740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
    Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
    Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
    [No Abstract]   [Full Text] [Related]  

  • 18. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.
    Maurer M; Staubach P; Raap U; Richter-Huhn G; Bauer A; Ruëff F; Jakob T; Yazdi AS; Mahler V; Wagner N; Lippert U; Hillen U; Schwinn A; Pawlak M; Behnke N; Chaouche K; Chapman-Rothe N
    Clin Exp Allergy; 2017 May; 47(5):684-692. PubMed ID: 28160338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective.
    Asero R; Canonica GW; Cristaudo A; Fierro MT; Girolomoni G; Marzano AV; Nettis E; Pepe P; Pigatto P; Rossi O
    Curr Opin Allergy Clin Immunol; 2017 Dec; 17(6):453-459. PubMed ID: 28968274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.